Israeli Drug Trial Shows Promise for Celiac Disease Patients
Israeli pharmaceutical company Teva announced significant positive results from a clinical trial of an experimental antibody for adults with celiac disease. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prevention of intestinal damage caused by gluten exposure compared to a placebo, after eight weeks of treatment.
The study involved 50 adults with celiac disease. The experimental antibody, TEV '408, not only prevented gluten-induced intestinal damage but also showed a positive effect in reducing intestinal inflammation and improving digestive symptoms when compared to a placebo. The antibody was found to be well-tolerated, with no safety concerns identified to date.
Dr. Eric Hughes, Teva's Senior Vice President and Head of Global R&D and Chief Medical Officer, stated that gluten-free diets, while the only option for celiac patients, often still leave individuals suffering from symptoms, intestinal damage, and a significant impact on their daily lives. He highlighted that these trial results underscore the potential to move beyond managing gluten exposure and to treat the disease at its biological source.
Hughes added that the findings strengthen Teva's confidence in focusing on the IL-15 pathway as an approach to reduce immune-mediated intestinal damage. The company is advancing the development of this potential new treatment for celiac disease.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.